Previous Article | Next Article 
Journal of Virology, December 2001, p. 11791-11802, Vol. 75, No. 23
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11791-11802.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Interaction of Zyxin, a Focal Adhesion Protein,
with the E6 Protein from Human Papillomavirus Type 6 Results in Its
Nuclear Translocation
Yan Yan
Degenhardt1 and
Saul
Silverstein2,*
Departments of
Pharmacology1 and
Microbiology,2 College of Physicians and
Surgeons, Columbia University, New York, New York 10032
Received 16 May 2001/Accepted 5 September 2001
 |
ABSTRACT |
Zyxin, a focal adhesion molecule, interacts specifically with the
E6 protein from human papillomavirus (HPV) type 6 in a yeast two-hybrid
screen of a cDNA library prepared from human keratinocytes. Zyxin does
not interact significantly with E6 proteins from HPV types 11, 16, or
18. The interaction was confirmed by in vitro and in vivo analyses and
it requires the LIM domains (Lin-11, Isl-1, and Mec-3 [G. Freyd,
S. K. Kim, and H. R. Horvitz, Nature 344:876-879, 1990]) found at the carboxyl terminus of
zyxin. Cotransfection of E6 from HPV (6E6) and
zyxin results in the accumulation of zyxin in the nucleus where it can
function as a transcriptional activator. 6E6
can also mobilize endogenous zyxin to the nucleus.
 |
INTRODUCTION |
Human papillomaviruses (HPVs) are
responsible for hyperproliferation of cutaneous and mucocutaneous
epithelial cells that can lead to propagation of benign
(30) or malignant (81) lesions depending on
the virus type. The E6 and E7 proteins encoded by mucocutaneous
high-risk types interact with p53 (65, 77) and the
retinoblastoma (Rb) protein family (50), respectively, and transform cells in culture (10, 35, 39, 49, 74). In contrast, the E6 and E7 proteins encoded by low-risk viruses do not
interact with these proteins and are not typically associated with
events that lead to cell transformation (6).
The E6 proteins encoded by HPVs contain about 150 amino acids and
possess two Cys-X-X-Cys zinc fingers that bind zinc (5). While host proteins that interact with the E6 protein from both low-
and high-risk HPVs (22, 44, 45, 54, 69) or only from
high-risk HPVs have been identified (16, 26-28, 40, 42, 47, 57,
60, 70), no specific interaction between low-risk E6 and host
proteins has been described. Here we report that low-risk E6 from HPV
type 6 (6E6) interacts with zyxin, a focal
adhesion protein (7).
Focal adhesion plaques are discrete areas on the cell membrane where
the cells contact the underlying substratum or each other (36,
75). They are also the sites where multiple protein complexes involved in signaling assemble (15). Focal adhesions
appear to represent transmembrane connections between the extracellular matrix and the cytoskeleton. Thus, it is not surprising that disrupted focal adhesions are frequently associated with the transformed phenotype (14). The E6 proteins from bovine papillomavirus
and high-risk HPV interact with paxillin, another focal adhesion
protein (13, 70, 71). This interaction may in part account
for the disruption of actin fiber organization when bovine
papillomavirus type 1 E6 is overexpressed in cells (70).
Zyxin has features reminiscent of a signaling protein. Relative to the
structural components of focal adhesions such as vinculin and
-actinin it is present at low abundance in cells and it is phosphorylated at multiple sites in vivo (18).
Structurally, it has a proline-rich domain at its N terminus and
multiple LIM (Lin-11, Isl-1, and Mec-3 [25])
domains in its carboxy-terminal half (8). Both domains are
thought to be involved in protein binding (59, 66). The
proline-rich domain associates with SH3 domains that are found in a
number of protein components in signal transduction pathways such as
the human proto-oncogene product Vav (38). The LIM domain
is a double-zinc-finger motif that is present in a number of proteins
involved in the regulation of cell proliferation and differentiation
(29, 61, 63). Zyxin also possesses a nuclear export
sequence, and chicken zyxin shuttles between the nucleus and focal
adhesions (52). These characteristics suggest a role for
zyxin as a messenger that relays information from sites of cell
adhesion to the nucleus.
 |
MATERIALS AND METHODS |
Plasmids. (i) HPV E6 plasmids.
The E6 constructs
6E6-Gal4-BD and
18E6-Gal4-BD for yeast two-hybrid assays,
glutathione S-transferase (GST)-6E6,
GST-11E6, GST-16E6, and
GST-18E6 for GST binding assays,
6E6-pET and 18E6-pET for in
vitro translation, and 6E6-Myc and
18E6-Myc for mammalian cell transfections were
described previously (22). The EcoRI and
BamHI fragments containing the 11E6
and 16E6 coding sequences were cloned into pAS2-1
(Clontech, Palo Alto, Calif.) to generate 11E6-Gal4-BD and
16E6-Gal4-BD. An NcoI/BamHI
fragment from 11E6-Gal4-BD was cloned into pET21
(Novagen, Madison, Wis.) to generate 11E6-pET. The sequence encoding 11E6 was released from
11E6-pET as an NcoI/NotI fragment, end filled, and cloned between the PmeI and
NotI sites in pmycpl.1 (11) to construct
11E6-Myc. The EcoRI/BsmI
fragment containing the N-terminal 37 amino acids of
11E6 was ligated to the
BsmI/BamHI fragment containing amino acids 37 to
150 of 6E6 and the resulting
11/6E6 fusion was cloned between EcoRI
and BamHI sites in pAS2-1 to construct
11/6E6-Gal4-BD. The NcoI fragment from
11/6E6-Gal4-BD was filled with Klenow enzyme and
cloned into the PmeI site in pmycpl.1 to generate
11/6E6-Myc. The MfeI/NotI fragment from 11/6E6-Myc was cloned between the
EcoRI and NotI sites in the vector pALEX
(53) to construct GST-11/6E6.
(ii) Zyxin constructs.
Full-length zyxin cDNA in pBluescript
KS(
) (Stratagene, La Jolla, Calif.) was kindly provided by Mary
Beckerle (Department of Biology, University of Utah, Salt Lake City,
Utah). An EcoRI fragment from this construct was cloned into
pET21b (Novagen) to create zyxin-pET for in vitro transcription and
translation. The same fragment was also cloned into a eukaryotic
expression vector, pCF2H (58), to generate zyxin-Flag. The
NcoI-EcoRI fragment was cloned into pAS2-1 for
zyxin-Gal4-BD and into pACTII (Clontech) for zyxin-Gal4-AD. The
NcoI-HincII fragment of full-length zyxin cDNA
was ligated between the NcoI and SmaI sites of
vectors pAS2-1 and pACTII to construct zyxin deletion mutants
Zy-5'-Gal4-BD and Zy-5'-Gal4-AD, respectively. The insert in the
construct Zy-5'-Gal4-AD was released with NcoI and
EcoRI and cloned into pET21d to generate Zy-5'-pET for in
vitro translation. Other zyxin deletion mutants containing only LIM
domains were all generated using PCR with primers having an
NcoI site in the 5' primers and an EcoRI site in
the 3' primers. The DNA sequence of each product was determined to
ensure that there were no mutations. The primers for LIM-1+2+3 were
5'-GGCAGACCATGGCTGTCAACGAACTCTGC-3' and
5'-GGGCCTGAATTCACTCAGGTCTGGGCTCTAG-3'. To generate LIM-1+2,
the 5' primer was the same as for LIM-1+2+3, but the 3' primer was
5'-GCAGACGGAATTCCTCGGGGCGTACTGCTTG-3'. For LIM-2+3, the 3'
primer was the same as that used for generating LIM-1+2+3, but the 5'
primer was 5'-CGTACTCCATGGGCTGTTACACTGACACCC-3'. For LIM-3,
the same 3' primer as for LIM-1+2+3 was used in conjunction with the 5'
primer 5'-ACTGTGCCATGGACTACCACAAGCAGTACGCC-3'. For LIM-1,
the 5' primer was the same as that used for LIM-1+2+3, and the 3'
primer was 5'-GCAGGTGGAATTCTTCTCCAGGGTGTCAGTG-3'. The NcoI-EcoRI fragments of these deletion mutants
were cloned into pAS2-1 to make Gal4-BD fusion proteins and pACTII to
make Gal4-AD fusion proteins. The NcoI-EcoRI
fragment of LIM-1+2+3 was also cloned into pET21d for in vitro
translation. The shortest zyxin clone from the two-hybrid library
screen, containing zyxin amino acids 299 to 572, was fused in frame
with Gal4-AD in pGAD10 (Clontech) and was named 6(3)-Gal4-AD. The
insert was released with NdeI and SalI and cloned
into pAS2-1 to construct 6(3)-Gal4-BD. For activation assays in
mammalian cells, zyxin-Gal4-AD was digested with NcoI, the
ends were filled with Klenow, and the plasmid was digested
again with SacI to release the insert to be ligated between the SmaI and SacI sites in pSG424
(62). These manipulations generated FL-M-GBD, a
full-length zyxin-Gal4-BD fusion that is expressed in mammalian cells.
Zy-5'-M-GBD was constructed the same way. The LIM-1+2+3 DNA fragment
was released with BglII, end filled, digested with
SacI, and ligated into the same SmaI and
SacI sites in pSG424 to create LIM-M-GBD.
(iii) Other constructs.
The PKC-Flag construct was from
Jae-Woe Soh (Department of Genetics, Columbia University, New York,
N.Y.). The Gps2-Flag construct was previously described
(22). RL-TK has a Renilla luciferase gene under
the control of a basic thymidine kinase promoter and was purchased from
Promega (Madison, Wis.). PG5-luc was described before
(80).
Yeast two-hybrid assays. (i) Yeast two-hybrid library
screen.
A human foreskin keratinocyte cDNA library containing
5 × 106 independent clones that was
constructed using both oligo-dT and random priming and cloned in pGAD10
to create Gal4-AD fusions was purchased from Clontech. The library was
screened as previously described (22).
(ii) Yeast strains and transformation.
Saccharomyces
cerevisiae strains YGH1 and L40 were used for
transformation of Gal4-BD fusion proteins and LexA fusion proteins, respectively. Strains Y187 and Y190 were from Clontech. All strains were maintained at 30°C on YPD (20 g of Difco Peptone/l, 10 g of yeast extract/l, 2% glucose) plates. Transformation and selection on Leu
Trp
SD (6.7 g of
amino acid-free yeast nitrogen base/l, 2% dextrose, 100 ml of 10×
dropout solution/l) plates was performed as described in the Clontech
Matchmaker System manual.
(iii) Filter lift assay for
-galactosidase (
-Gal)
activity.
Four to six days after transformation, the yeast
colonies were lifted onto nitrocellulose membranes (Schleicher & Schuell, Keene, N.H.), and the cells were lysed by freezing at
80°C
for 20 min and thawing at room temperature. The filter disks were placed onto Whatman paper soaked in 2 ml of Z buffer (60 mM
Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM
MgSO4, 0.3%
-mercaptoethanol) containing 0.33 mg of 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal) per ml and incubated at 37°C for 1 to 3 h.
(iv) Liquid
-Gal assay.
Individual yeast colonies were
picked into 3 ml of Leu
Trp
SD medium and grown to stationary phase.
They were then diluted 1:30 in medium and grown to an optical density
at 600 nm (OD600) of 0.4 to 0.6. The cells were
collected by centrifugation at 1,500 × g for 5 min at
4°C and washed once with Z buffer. The cell pellets were resuspended
in 250 µl of Z buffer, and the cells were lysed following the
addition of 200 µl of ice-cold acid-washed glass beads by vigorous
mixing three times for 1 min each. The cell lysates were clarified by
centrifugation at 3,000 × g for 5 min at 4°C. Total
protein concentrations were determined by the method of Bradford
(12). For
-Gal assays, 200 µl of 4-mg/ml
o-nitrophenyl-
-D-galactopyranoside (ONPG) was added to 150 µl of cell extract diluted in 800 µl of Z
buffer, and the mixture was incubated at 30°C until a pale yellow color developed. The reaction was stopped by adding 500 µl of 1 M
Na2CO3, and the
OD420 was determined. Z buffer alone incubated with ONPG was used as a control for measuring the
OD420. The
-Gal units were calculated from the
equation U = (1,000 × OD420)/(t × mg),
where t is the reaction time in minutes and mg is
the total amount of lysate protein in milligrams that was added to the
reaction (4).
(v) In vitro transcription and translation.
pET21 clones
were subjected to in vitro transcription and translation using TNT
Coupled Reticulocyte Lysate systems for zyxin or TNT Coupled Wheat Germ
systems for E6 proteins as described by the manufacturer (Promega). For
HPV E6, [35S]cysteine (Amersham Pharmacia
Biotech, Piscataway, N.J.) was used for labeling, while zyxin was
labeled with [35S]methionine (Amersham
Pharmacia Biotech).
GST protein purification and GST pull-down assays. (i) GST
protein purification.
Escherichia coli strain BL21 was
the host for production of GST-E6 fusion proteins. The cultures were
grown at 30°C. Five hundred milliliters of cell culture was induced
with 0.8 mM isopropyl-
-D-thiogalactopyranoside (IPTG) when the OD600 reached 0.5 to 0.8. After
four to six more hours, cells were harvested and resuspended in 20 ml
of cold phosphate-buffered saline (PBS) containing 1 mM
phenylmethylsulfonyl fluoride, 0.1 mM dithiothreitol, and 0.2 mg of
lysozyme per ml. All subsequent steps were performed at 4°C. Cells
were lysed by sonication (three times for 20 s each) after the
addition of Triton X-100 to 1%. The cell lysate was clarified by
centrifugation at 20,000 × g for 15 min. Six hundred
microliters of preswollen glutathione-agarose beads (Sigma, St. Louis,
Mo.) was added to the lysate and mixed at 4°C for 2 h. The beads
were then washed four times with 45 ml of PBS plus 1% Triton.
(ii) GST pull-down assays.
Forty microliters of a 50%
suspension of glutathione-agarose beads containing 3 to 5 µg of GST
fusion protein was blocked at 4°C for 0.5 h in 500 µl of
binding buffer (20 mM Tris-HCl [pH 7.5], 50 mM KCl, 0.5 mM EDTA, 3%
bovine serum albumin [BSA], 1% NP-40). The beads were pelleted at
7,000 rpm for 20 s in an Eppendorf 5415C microcentrifuge
and resuspended in 100 µl of binding buffer. Two microliters of
35S-labeled in vitro translation product was
added to the mix and the binding was performed at 4°C for 1 h.
The beads were then washed six times with 1 ml of binding buffer and
boiled for 5 min in 15 µl of sodium dodecyl sulfate (SDS) loading
buffer prior to analysis by SDS-polyacrylamide gel electrophoresis
(PAGE) (46). After electrophoresis, the bound
35S-labeled protein was detected by autoradiography.
Far Western analysis.
Three to five micrograms of GST-E6
proteins was subjected to SDS-PAGE and then transferred onto a
nitrocellulose membrane. After transfer, the membrane was blocked
overnight in PBS containing 0.1% Tween 20 (Sigma) with 4% BSA to
renature the proteins. The membrane was then washed with HEPES binding
buffer (25 mM HEPES [pH 7.9], 50 mM NaCl, 1 mM EDTA, 1 mM
dithiothreitol, 0.5% BSA) and blotted with in vitro translated
35S-zyxin in the same buffer for 1 h at room
temperature. The membrane was then washed five times with HEPES binding
buffer, dried, and exposed to film.
Cell culture and transfections.
Cos7, Mewo, and
293T cells were grown and maintained in Dulbecco's modified Eagle's
medium (Gibco BRL, Grand Island, N.Y.) containing 10% fetal bovine
serum (HyClone Laboratories Inc., Logan, Utah). Mewo cells are a human
melanoma cell line that was obtained from Charles Grose, University of
Iowa. 293T cells were transfected by the calcium phosphate
precipitation method as previously described (78). Cos7
and Mewo cells were transfected with Lipofectamine Plus reagents from
Gibco BRL following the manufacturer's protocol.
Coimmunoprecipitation.
For coimmunoprecipitation assays,
293T cells in 10-cm-diameter dishes were transfected with 20 µg of
zyxin-Flag, Gps2-Flag, PKC-Flag, or vector DNA. Thirty-six hours after
transfection, cells were collected into ice-cold PBS and pelleted at
1,700 × g for 5 min at 4°C. All of the following
steps were performed on ice. The cells were resuspended in 1 ml of
lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40, 100 mM
NaF, 10% glycerol, 200 µM
Na3VO4, 10 µg of
aprotinin per ml, 10 µg of leupeptin per ml, 1 mM
phenylmethylsulfonyl fluoride) and sonicated for 1 min. After
centrifugation at 14,000 rpm in a microcentrifuge for 5 min, the cell
lysate was precleared by incubation with 50 µl of a 10% suspension
of IgGsorb (The Enzyme Center, Malden, Mass.) in lysis buffer for 15 min and then the beads were pelleted. The supernatant was transferred
to a fresh tube, and the total protein concentration was determined.
One milligram of cell protein in a total volume of 500 µl of lysis
buffer was mixed with 10 µl of
[35S]cysteine-labeled in vitro-translated E6
proteins for 2 h to overnight at 4°C. One hundred microliters of
anti-Flag M2 affinity gel (Kodak, New Haven, Conn.) was added to the
mix, and incubation was continued for another hour. The beads were
harvested and washed five times with 1 ml of lysis buffer per wash by
rotating at 4°C for 5 min and then centrifuging the beads in a
microcentrifuge at 7,000 rpm for 20 s. After the final wash, the
beads were boiled for 5 min in SDS loading buffer and subjected to
SDS-PAGE. The coprecipitated E6 proteins were visualized with a phosphorimager.
In other experiments 106 Cos7 cells in
60-mm-diameter dishes were transfected with 1 µg of zyxin-Flag
construct or Gps2-Flag construct and 4 µg of the
18E6-Myc construct or 0.9 µg of the 6E6-Myc construct. At 36 h after
transfection cells were labeled with
35S-translabel (ICN, Irvine, Calif.) for 3 h. Cell lysates were prepared as described above except that the
concentration of NP-40 in the lysis buffer was 0.1% and the pH of the
solution was 8.0. Flag-tagged proteins were immunoprecipitated as
described above and the coprecipitated proteins were separated on a 4 to 12% Bis-Tris gel (Novex, San Diego, Calif.) and visualized by
autoradiography. In another set of experiments, cell lysates were
prepared from unlabeled, transfected Cos7 cells and Flag-tagged
proteins were immunoprecipitated as described above. After separating
the coprecipitated proteins by electrophoresis on a 15% SDS gel, the
proteins were transferred onto a nitrocellulose membrane, and the E6
proteins and the Flag-tagged proteins were reacted with an anti-Myc
antibody and an anti-Flag antibody, respectively. Immunoreactive
proteins were detected using a goat anti-mouse antibody to which
horseradish peroxidase was conjugated (Kirkegaard and Perry,
Gaithersburg, Md.) and visualized using a chemiluminescent substrate
followed by exposure to Biomar blue film (Marsh Biochemical, Rochester, N.Y.).
Luciferase assay.
Cos7 cells in 35-mm-diameter plates were
harvested 36 h after transfection into 300 µl of 1× lysis
buffer (Dual-Luciferase Reporter Assay system; Promega) per well. The
luciferase activities from both firefly and Renilla
luciferase constructs were quantified with a Berthold Lumat LB9501
luminometer (Wallac Inc., Gaithersburg, Md.) using the reagents and
protocol provided by the manufacturer.
Immunofluorescence.
Transfected cells grown on cover slides
in six-well plates were fixed in 4% paraformaldehyde for 10 min at
room temperature. They were then permeabilized with 0.5% NP-40 in PBS.
After blocking in 10% normal goat serum for 0.5 h, the cells were
stained with anti-zyxin to detect zyxin or anti-Myc (BAbCO, Richmond,
Calif.) to detect E6-Myc. Anti-zyxin is an antibody made by immunizing a rabbit with a peptide corresponding to zyxin amino acids 138 to 207. For anti-zyxin the dilution was 1/50 while for anti-Myc the dilution
was 1/100. To detect GBD fusions a 1/50 dilution of a monoclonal
anti-GBD serum (Clontech) was used. After 0.5 h of incubation with
the primary antibodies, cells were washed six times with PBS before
incubating in a 1/200 dilution of anti-rabbit-rhodamine and
anti-mouse-fluorescein isothiocyanate (Kirkegaard & Perry) for
0.5 h. Cells were washed six times before mounting onto slides. Preparations were viewed using a Leitz Dialux microscope with optical
systems for the selective visualization of fluorescein or rhodamine.
Representative fields of cells were photographed using a Kodak DC120
digital camera adapted for photomicroscopy (Eastman Kodak, Rochester,
N.Y.). Images were acquired on a Macintosh computer using the Kodak
plug-in for Adobe Photoshop. Digitized images were assembled using
Adobe Illustrator, v. 9.02, on a Macintosh computer and printed on a
Shinko dye sublimation printer. For confocal imaging, an Alexa Fluor
546-conjugated anti-rabbit immunoglobulin G and an Alexa Fluor
488-labeled anti-mouse immunoglobulin G (Molecular Probes, Inc.,
Eugene, Oreg.) were used to enhance the sensitivity of the detection. A
Zeiss LSM 510 NLO Multiphoton confocal microscope and its associated
software was used to capture the images, which were transferred to
Adobe Photoshop, v. 5.5, for compiling before assembly using Adobe
Illustrator, v. 9.02, and were then printed on an Epson 900 inkjet printer.
 |
RESULTS |
A yeast two-hybrid library screen identifies zyxin as a protein
partner for 6E6.
To identify novel proteins that
interact with high-risk or low-risk E6 proteins we conducted a yeast
two-hybrid library screen using low-risk 6E6 or
high-risk 18E6 fused to the DNA binding domain of
Gal4 (Gal4-BD) as baits. The yeast two-hybrid library contained Gal4
activation domain (Gal4-AD) fusions of cDNAs from normal human foreskin
keratinocytes, which are the natural host cells for HPV. Yeast were
cotransformed with the Gal4-BD vector or a Gal4-BD fusion with laminin
and the putative interacting clones to eliminate false positives and
the positive clones that survived this screen were tested further.
Positive interactors were tested in two other yeast strains, Y190 and
Y187, besides the YGH1 strain that was used for screening the library.
The DNA sequences of the clones that were positive in all three strains of yeast were determined. Of the 10 clones that interacted with 6E6-Gal4-BD 9 encoded various lengths of zyxin
and the other encoded Gps2 (22). However, zyxin did not
appear even once among the positive clones using
18E6-Gal4-BD as bait. When cotransformed with
18E6-Gal4-BD, none of the Gal4-AD fusions of the
various zyxin clones showed positive interaction as judged by a
-Gal filter lift assay (data not shown), suggesting that zyxin interacted with 6E6 but not 18E6. A
full-length cDNA of zyxin was acquired (48) and tested for
interaction with E6 proteins in the yeast two-hybrid system. Again,
only yeast colonies cotransformed with the zyxin-Gal4-AD fusion and
6E6-Gal4-BD but not
18E6-Gal4-BD or Gal4-BD vector alone turned blue
in the
-Gal lift assay (data not shown), indicating that zyxin
interacts with 6E6 specifically.
Zyxin and 6E6 interact in vitro.
To test if zyxin
could interact with 6E6 directly, in
vitro-translated, 35S-labeled full-length zyxin
was allowed to interact with identical amounts of immobilized GST and
GST fusions with 6E6 or
18E6. After binding in the presence of 50 mM KCl,
the beads with bound proteins were washed extensively with buffers
containing increasing concentrations of salt. At a 50 mM
[K+] 6.9% of the
35S-labeled zyxin was retained by beads
containing GST-6E6, and at 250 mM salt 4.9% of
the input remained on the beads (Fig. 1). In contrast, <1% of zyxin was retained by beads containing
GST-18E6 even at 50 mM
[K+]. These results demonstrate that the
interaction between 6E6 and zyxin is stable and
can exist under physiological conditions. Moreover, in this assay
system zyxin is preferably bound by 6E6 (Fig. 1).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Zyxin binding to GST-E6 proteins. In vitro-translated
and 35S-labeled zyxin was allowed to interact with
identical amounts of purified GST-6E6,
GST-18E6, or GST alone. After binding at 50 mM
[K+], the beads were washed extensively with buffers
containing 50, 150, or 250 mM salt. Bound proteins were eluted and
separated by SDS-PAGE. Zyxin was visualized by autoradiography of the
dried gel. The numbers above each lane are the millimolar salt
concentrations used for washing the beads.
|
|
To confirm the interaction between 6E6 and zyxin,
293T cells were transfected with DNA constructs that expressed
Flag-tagged zyxin, Gps2, or PKC or only the Flag epitope. We previously
demonstrated that Gps2 is able to interact with both
6E6 and 18E6
(22). The PKC-Flag vector served as a negative control.
Thirty-six hours after transfection, cells were collected and cell
lysates were prepared. In vitro-translated
35S-labeled 6E6 or
18E6 was mixed with the same amount of protein from each cell lysate (for 2 h to overnight) before the
Flag-tagged proteins were immunoprecipitated with an anti-Flag
antibody. 6E6 coprecipitated with both Gps2 and
zyxin but not with Flag or PKC-Flag (Fig.
2A, upper panel). However,
18E6 only coprecipitated with Gps2 and not with
zyxin (Fig. 2A, lower panel), further confirming that zyxin interacts
specifically with 6E6. Western analysis using an
anti-Flag antibody demonstrated that all of the Flag proteins were
retained on the beads at comparable levels (Fig. 2B).

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 2.
Coimmunoprecipitation of 6E6 with zyxin.
293T cells were transfected with DNA encoding zyxin-Flag, Gps2-Flag,
PKC-Flag, or the Flag vector alone. Thirty-six hours after
transfection, cell lysates were prepared and mixed with in
vitro-translated and 35S-labeled 6E6 or
18E6 (A). Flag-tagged proteins were then immunoprecipitated
with an anti-Flag antibody and the coprecipitated E6 proteins were
visualized with a phosphorimager after separation by SDS-PAGE. The Flag
proteins retained on the Sepharose beads after immunoprecipitation were
detected by Western analysis with an anti-Flag antibody after boiling
the beads in SDS loading buffer and separating the bound proteins by
SDS-PAGE (B). Cos7 cells were transfected with DNA encoding Flag-tagged
zyxin or Gps2 alone, E6-Myc constructs alone, or the combination of a
Flag-tagged protein construct and an E6 construct. Thirty-six hours
after transfection, cells were labeled with 35S-translabel
for 3 h, and the cells were harvested and lysed. Transfected cell
lysates with equal amounts of total protein were reacted with an M2
anti-Flag affinity gel. E6 proteins that were spun out with the gel
were visualized by autoradiography following SDS-PAGE separation of the
bound proteins. The bands corresponding to zyxin, Gps2, and the E6
proteins are marked with arrows (C). (The protein levels of E6 in each
of the transfected cell lysates were detected by Western analysis using
an anti-Myc antibody after SDS-PAGE and are shown in the lower part of
this panel.) This experiment was repeated without labeling the cells.
After separating the proteins that eluted off of the gel by SDS-PAGE,
the E6 proteins and the Flag-tagged proteins were detected by Western
analysis using an anti-Myc antibody (upper panel) and an anti-Flag
antibody (lower panel), respectively (D).
|
|
Zyxin and 6E6 interact in vivo.
To test if the
interaction between 6E6 and zyxin occurs in
mammalian cells, Cos7 cells were transfected with DNA constructs that
expressed Flag-tagged zyxin or Gps2, Myc-tagged
6E6 or 18E6, or
combinations of a Flag-tagged and a Myc-tagged construct. Thirty-six hours posttransfection, cells were labeled with
35S for 3 h and then cell lysates were
prepared. Flag-tagged proteins were immunoprecipitated with an
anti-Flag affinity gel. Proteins that coprecipitated with the
Flag-tagged proteins were separated by SDS-PAGE and E6 proteins were
identified based on their migration after autoradiography. The beads
did not retain either 6E6 or 18E6 alone (Fig. 2C). In the cells cotransfected
with zyxin, 6E6 but not
18E6 was detected on the beads, even though
18E6 was readily detected on the beads incubated
with the extract from cells cotransfected with Gps2 (Fig. 2C). Western
analysis using an anti-Myc antibody revealed that E6 protein levels
were similar in the presence or absence of the Flag-tagged proteins
(Fig. 2C, lower panel). Furthermore, 18E6 was
present at higher levels than 6E6 in the lysates
but did not coprecipitate with zyxin (Fig. 2C, lower panel). These experiments demonstrate that 6E6 but not
18E6 interacts with zyxin in vivo. Because
identification of E6 in the previous experiment was based on migration
and its presence or absence in the appropriate lanes we sought to
confirm this observation using an alternative approach. Accordingly,
the experiment was repeated and E6-Myc proteins that interacted with
Flag-tagged zyxin or Gps2 were identified by Western blot analysis
using an anti-Myc antibody. Analysis of the resulting gel (Fig. 2D)
demonstrates that 6E6 but not
18E6 interacts with zyxin, confirming the results
of the experiment shown in Fig. 2C.
Zyxin interacts with 6E6 but not with other E6
proteins.
Because zyxin was found to interact with low-risk
6E6 but not with high-risk
18E6, we next asked if it interacted with other E6 proteins. To test for interactions, yeast cells were cotransformed with DNA constructs expressing full-length zyxin-Gal4-AD and -Gal4-BD fusions with 6E6, 18E6,
11E6, or 16E6. Assays for
-Gal activity were performed on extracts from the transformants and
the
-Gal units from this assay were used to determine if there was
an interaction between zyxin and the various E6 proteins. The results
of this assay suggest that only 6E6 interacts
with zyxin and that none of the other E6 proteins, including
11E6, another low-risk E6 protein, interact (Fig.
3A). In addition, cotransformation of yeast with each of the E6-Gal4-BD constructs and Gal4-AD vector DNA
failed to activate the
-Gal reporter (data not shown). To verify
this finding, we tested the binding between zyxin and different E6
proteins in another system. Full-length zyxin was labeled with 35S by coupled in vitro transcription-translation
and mixed with identical amounts of GST-E6 fusion proteins bound to
agarose beads. Again, zyxin was retained significantly only by
GST-6E6 (3.3% of input) and not by any of the
other GST fusion proteins tested, including
GST-11E6 (<0.5%) (Fig. 3B). Figure 3C
demonstrates that similar amounts of GST fusion proteins were used in
the binding assay. The results of these experiments suggest that the
interaction between zyxin and 6E6 might be unique
and not a general property of low-risk E6 proteins.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Interaction between E6 proteins and zyxin. (A) Plasmid
DNAs encoding Gal4-BD fusions with 6E6, 11E6,
16E6, or 18E6 were cotransformed with a
construct expressing a zyxin-Gal4-AD fusion into yeast strain YGH1.
Liquid -Gal assays were performed on the cotransformed colonies as
described in Materials and Methods. The numbers for the -Gal units
are the averages of three separate experiments. (B) In vitro-translated
35S-labeled zyxin was allowed to bind to the same amounts
of purified GST-E6 fusion proteins or GST alone as described in
Materials and Methods. The bound zyxin protein was visualized by
autoradiography after SDS-PAGE analysis. One-twentieth of the zyxin
input was also electrophoresed on the gel. (C) Coomassie brilliant blue
staining of the gel after SDS-PAGE was used to detect the amount of
each GST fusion protein used for this assay.
|
|
6E6 and 11E6 are considered
to be highly homologous because, in a phylogenetic analysis, they fall
on the same branch within subgroup B of HPVs (51).
However, in both yeast two-hybrid and GST binding assays, no
interaction between zyxin and 11E6 was detected
(Fig. 3). Therefore, we aligned and compared the amino acid sequences
of these two proteins and noted that there were 28 differences. When
these amino acids are grouped according to their chemical composition
(41), 17 of the 28 differences are not conserved (Fig.
4A). Because a Gal4-BD fusion to a
6E6 mutant that lacks the first 36 amino acids
also failed to interact with a Gal4-AD fusion of zyxin in yeast (data
not shown) a chimeric E6 gene was constructed. The protein encoded by
this construct, 11/6E6, was composed of the first
36 amino acids from 11E6 and amino acids 37 to
150 from 6E6. When this construct was examined in
a yeast two-hybrid assay the chimeric protein did not interact with
zyxin (Fig. 4B). To confirm this result, 6E6,
11E6, and 11/6E6 GST fusion
proteins were prepared and used as targets in a far Western assay with
radiolabeled zyxin. This analysis demonstrates that under these
conditions only 6E6 was able to bind zyxin (Fig. 4C, upper panel). The lower panel of Fig. 4C shows that similar amounts
of GST-E6 proteins were present in each lane on the filter. This
experiment further confirms our observation that zyxin selectively interacts with 6E6 but not with
11E6 and also suggests that sequences in the
amino terminus may contribute to this selectivity.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Specificity of zyxin interactions with 6E6.
(A) The amino acid sequences of 6E6 and 11E6
are aligned for comparison and only the amino acids in 11E6
that differ are shown. The vertical line denotes the junction between
the sequences from 11E6 and the sequences from
6E6 in the chimeric protein 11/6E6. (B)
Schematic representations of E6 proteins and their abilities to
interact with zyxin in the yeast two-hybrid system or in the far
Western analysis are shown. +, zyxin interaction is seen; , no
interaction; ND, not tested. (C) Equal amounts of GST fusion proteins
with 6E6, 11/6E6, or 11E6 were
tested for binding to in vitro-translated 35S-zyxin in a
far Western analysis as described in Materials and Methods, and the
resulting autoradiograph is shown in the upper panel. The GST-E6 fusion
proteins used for this assay were detected by Coomassie brilliant blue
staining and are shown in the lower panel.
|
|
The LIM domains in zyxin are responsible for 6E6
binding.
Zyxin has two well-described protein-binding motifs, the
proline-rich domain at the N terminus and the three adjacent LIM domains that occupy the C-terminal 189 amino acids (Fig.
5). Each of the zyxin clones identified
in the yeast two-hybrid library screen contained all three of the LIM
domains, but most lacked an intact proline-rich domain. To identify
regions in zyxin that are responsible for 6E6
binding, deletion mutants were constructed and tested for
6E6 binding. Zy-5' contains all of the N-terminal amino acids that precede the LIM domain region. LIM-1+2+3 contains all
three LIM domains, while LIM-1+2 contains LIM domains 1 and 2, LIM-2+3
contains LIM domains 2 and 3, LIM-1 contains the N-terminal LIM domain
1, and LIM-3 contains the C-terminal LIM domain 3 (Fig. 5). Each of
these deletion mutants was cloned as a Gal4-AD fusion and cotransformed
into yeast with 6E6-Gal4-BD. Filter lift assays revealed that the yeast colonies cotransformed with the
6E6-Gal4-BD construct and a full-length zyxin
construct (FL) or zyxin construct LIM-1+2+3, LIM-2+3, or LIM-3 turned
blue in the presence of X-Gal. However, cotransformation with zyxin
constructs lacking the LIM-3 domain, such as Zy-5', LIM-1+2, and LIM-1,
resulted in colonies that lacked detectable
-Gal activity (data not
shown). Thus, the LIM domains, but not the 5' proline-rich domain in
zyxin, were required for binding. Notably, it was LIM-3, the most
C-terminal LIM domain, that seemed to be essential for interaction with
6E6. To examine this further, colonies from each
cotransformation were picked and liquid
-Gal assays were performed.
These analyses supported our initial observation that the LIM domains
were required for the interaction and that the Zy-5' clone did not
produce a protein that interacted with 6E6 (Fig.
6A). They also revealed a requirement for
the LIM-3 domain because LIM-2+3 interacted while LIM-1+2 did not.
While LIM-3 is required, the other two LIM domains seemed to facilitate
the interaction, as the level of interaction with
6E6 (in descending order) was LIM-1+2+3 > LIM-2+3 > LIM-3 (Fig. 6A). Although colonies cotransformed with 6E6 and LIM-3 eventually turned blue in the
filter lift assay this interaction was so weak that the level of
-Gal activity was barely above background in the liquid
-Gal
assay (Fig. 6A). Because the Gal4-AD vector used for cloning zyxin has
a hemagglutinin (HA) tag, we were able to monitor the expression levels
of the deletion mutants in yeast by Western analysis using an anti-HA antibody. All of the zyxin deletion mutants were expressed in yeast
(Fig. 6B).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Schematic diagram of zyxin. The boundaries of zyxin and
the various zyxin deletion mutants constructed for this study are
shown, with 6(3) being the shortest clone that interacted with
6E6 in the two-hybrid library screen. The FPPPP homology,
the 5' proline-rich domain, and the three LIM domains at the C terminus
are identified.
|
|

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 6.
Identification of 6E6 interactive domains in
zyxin. (A) Yeast strain YGH1 was cotransformed with DNA constructs
encoding Gal4-AD fusions to zyxin deletions and 6E6-Gal4-BD
(+E6) or Gal4-BD vector ( E6). Data for the LIM proteins LIM-1+2+3
(1+2+3), LIM-2+3 (2+3), LIM-3 (3), LIM-1+2 (1+2), and LIM-1 (1) are
shown. Liquid -Gal assays were performed on the cotransformants as
described in Materials and Methods. The values are the average -Gal
units from three separate experiments. (B) Yeast cotransformants were
grown in Leu Trp liquid medium until the
OD600 reached 0.4 to 0.6. Cells were pelleted and boiled in
SDS loading buffer. Equal amounts of total cell extracts were subjected
to SDS-PAGE. The expression of the Gal4-AD fusion proteins was detected
by Western analysis using an anti-HA antibody. (C) Binding between
zyxin deletion proteins and GST-6E6. In vitro-translated
35S-labeled full-length zyxin (FL) or zyxin deletion mutant
proteins Zy-5' and LIM-1+2+3 were allowed to interact with the same
amount of GST-6E6 fusion protein or GST alone as described
in Materials and Methods. The bound proteins were separated by SDS-PAGE
and visualized by autoradiography. One-twentieth of the input of each
35S-labeled protein was loaded on the same gel to quantify
relative binding.
|
|
To confirm the specificity of this interaction, the FL, Zy-5', and
LIM-1+2+3 proteins were synthesized in vitro, labeled with 35S, and tested for binding to
GST-6E6 or GST purified from bacteria. While
LIM-1+2+3 and full-length zyxin bound GST-6E6 to
comparable levels, there was no detectable binding by Zy-5' (Fig. 6C).
None of the three zyxin proteins bound GST. These data agree with the results of the yeast two-hybrid assay and support our contention that
it is the LIM domains that are responsible for
6E6 binding.
Zyxin proteins are transactivators in yeast.
When the
full-length zyxin was fused to Gal4-BD it strongly activated the
-Gal reporter in yeast. A similar level of activation was observed
when zyxin was fused to LexA and transformed into the L40 strain (data
not shown). To identify the regions in zyxin that confer the
transactivation activity, the zyxin deletion mutants were fused to the
Gal4-BD and transformed into yeast YGH1, and liquid
-Gal assays were
performed on the transformants (Fig. 5 and
7). The full-length clone (FL) and a
construct containing amino acids 1 to 382 (Zy-5') displayed
transactivation activity, whereas a construct that expressed only the
three LIM domains (Lim-1+2+3) did not activate transcription when
expressed as a Gal4-BD fusion protein (Fig. 7). Thus, the region 5' of
the LIM domains in zyxin has transactivation activity in yeast. Western analysis using an anti-Gal4-BD antibody showed that all of the constructs containing LIM domains were expressed (data not shown).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 7.
Analysis of the transcriptional activator activity of
zyxin in yeast. Yeast strain YGH1 was transformed with DNAs expressing
the Gal4-BD fused to full-length zyxin (FL), zyxin amino acids 1 to 382 (Zy-5'), and LIM-1+2+3 (1+2+3). The nomenclature used to describe the
proteins is described in the legend for Fig. 5. Liquid -Gal assays
were performed on the yeast transformants and -Gal units are plotted
on the y axis.
|
|
Zyxin proteins have transactivation activity in mammalian
cells.
We next asked if zyxin can be an activator in mammalian
cells. DNAs expressing full-length zyxin or Zy-5', each of which
functioned as an activator in yeast, were cloned into a mammalian
expression vector as Gal4-BD fusions and cotransfected into Cos7 cells
with G5-luc, a luciferase reporter with multiple Gal4 binding sites in
its promoter. These constructs exhibited minimal or no transactivation activity when expressed by themselves (Table
1). While the
6E6-Myc and 11E6-Myc clones
each stimulated reporter activity, inclusion of
6E6-Myc in the cotransfections resulted in
stimulation of the transactivation activity of the full-length zyxin
construct but not of Zy-5' (Table 1). Indeed, Zy-5' alone had no higher
level of activation than empty vector. When cotransfected with
6E6 the level of activation was less than what
was detected with 6E6 alone. In contrast,
cotransfection of these constructs with 11E6
resulted in much lower levels of gene activation. The action of
11E6-Myc in the presence of FL-GBD is additive
whereas the readout from cotransfections with
6E6-Myc and FL-GBD reflect a synergistic response. This experiment suggests that exogenously expressed zyxin,
when bound to Gal4-BD, has transcriptional activation potential and
that this activity is synergistically enhanced by
6E6 when the interacting LIM domain is present in
the zyxin construct.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Analysis of the transcriptional activator activity of
zyxin in mammalian cells cotransfected with HPV E6
proteinsa
|
|
6E6 alters the cellular localization of ectopically
expressed zyxin proteins.
Because 6E6
stimulated transactivation by FL but not Zy-5' the cellular
localization of the respective Gal4-BD fusions was analyzed in Cos7
cells cotransfected with constructs encoding Myc-tagged
6E6 or the Myc epitope. Twenty-four hours after
transfection, cells were fixed and stained for zyxin and
6E6 using anti-zyxin and anti-Myc antibodies,
respectively. As shown in Fig. 8A and C
the FL and Zy-5' fusion proteins were found to localize predominantly to the cytoplasm. However, following cotransfection with
6E6, a portion of FL fusion protein was detected
in the nucleus where most of the 6E6 was
localized (Fig. 8B and F). Redistribution of the Zy-5' fusion protein
did not occur (compare panels C and D in Fig. 8), perhaps because it
lacks the LIM domains and therefore does not interact with
6E6 (Fig. 6).

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 8.
Cellular localization of zyxin. One-half of a microgram
of FL-M-GBD or Zy-5'-M-GBD DNA was cotransfected into Cos7 cells with
1.5 µg of a construct expressing 6E6-Myc (B, D) or the
Myc vector (A, C). Thirty-six hours after transfection, cells were
fixed and zyxin proteins were detected with a polyclonal rabbit
anti-zyxin antibody and visualized after interaction with a
rhodamine-conjugated anti-rabbit serum (A to D), while E6 proteins were
detected with a mouse monoclonal anti-Myc antibody followed by
fluorescein isothiocyanate-labeled anti-mouse antibody (E to H).
|
|
The demonstration that coexpression of 6E6, but
not 11E6, and a zyxin-Gal4-BD fusion results in
activation of a reporter and the finding that coexpression of
6E6 with ectopically expressed zyxin-Gal4-BD
resulted in nuclear localization of some of the fusion protein (Fig. 8)
led us to next ask if the cellular distribution of endogenous zyxin was
altered in response to expression of E6. Plasmids expressing Myc-tagged
6E6, 11E6,
18E6, or 11/6E6 were transfected into Mewo cells and examined by confocal microscopy following staining with antibodies specific for the Myc tag and zyxin.
Figure 9A to C is a series of images from
the same cells taken at three different depths of focus. It is clear
from these pictures that the signal generated by
6E6 is located in the nucleus. Each of the E6
proteins examined was located predominantly in the nucleus of
transfected cells (Fig. 9D, G, J, and M). When these same cells were
analyzed for the distribution of zyxin we noted nuclear fluorescence of
zyxin only in cells transfected with 6E6 (Fig.
9E, H, K, and N). Merging the images for E6 and zyxin confirms that
zyxin is only present in the nucleus of cells that coexpress
6E6 (Fig. 9F, I, L, and O). Thus,
6E6 has the capacity to alter the cellular
distribution of a protein that is normally found as part of the
cytoskeletal network and in adhesion plaques.

View larger version (101K):
[in this window]
[in a new window]
|
FIG. 9.
Distribution of endogenous zyxin in Mewo cells
cotransfected with E6 proteins. Mewo cells were transfected with DNA
constructs expressing 6E6-Myc (A to F),
11E6-Myc (G to I), 18E6-Myc (J to L), or
11/6E6-Myc (M to O). Thirty-six hours after transfection,
cells were fixed and the distribution of zyxin (A, B, C, E, H, K, and
N) and E6 (A, B, C, D, G, J, and M) in the cells was detected by
confocal microscopy as described in Materials and Methods. Panels A, B,
and C are the same image photographed at three different depths of
field to demonstrate that the E6 signal is nuclearly located. Panels F,
I, L, and O are the merged images of panels D and E, G and H, J and K,
and M and N, respectively.
|
|
 |
DISCUSSION |
E6 and E7, the major transforming proteins from HPV, do not
possess any known enzymatic activities. Rather, they promote cell proliferation by interacting with host cell factors and interfering with their normal functions. Several cell proteins have been identified as interaction partners for HPV E6. However, most of these only interact with high-risk HPV E6 (for review, see reference
43). Bak, Gps2, Mcm7, and p300 are the only four proteins
that have been described as interacting with E6 from both high-risk and low-risk HPVs (22, 44, 54, 69). Here we report the
identification and characterization of a protein that interacts
specifically with 6E6. This protein is zyxin, a
focal adhesion molecule. As a result of this interaction a portion of
the cell's zyxin translocates to the nucleus and can now serve as a
transcriptional activator.
We first identified the interaction between 6E6
and zyxin by screening a yeast two-hybrid library using
6E6 as bait. Subsequent analyses using GST
binding and coimmunoprecipitation demonstrated that
6E6 and zyxin interact both in vitro and in vivo
(Fig. 1 and 2). However, we were unable to detect any significant
interaction between 16E6 or
18E6 and zyxin in any of these assays (Fig. 3). This is the first instance of a protein that interacts preferably with
low-risk and not high-risk HPV E6. However, zyxin is not a general
protein partner for low-risk E6 proteins. In both the two-hybrid system
and GST binding assays 11E6, another closely related low-risk E6 protein, also failed to interact with zyxin. This
is not the first description of a protein that interacts with one type
of HPV E6 but not with the whole group of high-risk or low-risk HPV
E6s. E6-AP was found to interact with 18E6 with a
much lower affinity than with 16E6
(40) and IRF-3 interacts selectively with
16E6 (60).
HPV6 is detected in a higher percentage of genital warts than any other
HPV (30, 31). Although HPV6 is rarely found in cervical
tumors, tumors at other sites and Buschke-Lowenstein condylomata have
been reported to harbor HPV6 (9, 30). We do not know if
the interaction of 6E6 with zyxin enhances
replication of HPV6 in epithelial tissue. However, Hirota et al.
recently demonstrated that zyxin can control mitosis progression by
forming a regulatory complex with the h-warts/LATS1 tumor suppressor on the mitotic apparatus (37).
Zyxin is a protein with distinct structural features. The N-terminal
two-thirds consists of a proline-rich domain that interacts with Src
homology 3 domains and serves as a binding site for
-actinin and
Ena/VASP family members (19, 23, 38). These interactions enhance the production of actin-rich structures at the apical surface
of cells and contribute to their positioning (23, 24). The
C-terminal one-third of zyxin contains three LIM domains. The LIM
domain is a cysteine- and histidine-rich motif of approximately 60 amino acids in length (for review, see reference 66). Each LIM domain coordinates two Zn2+ ions. The LIM
motif is present in a number of proteins that are involved in the
control of gene expression and cell differentiation (2, 68, 73,
76). LIM motifs can also serve as an interface for protein
interactions (66) and this motif in zyxin interacts with
cysteine-rich protein family members that are involved in differentiation (20). By analyzing the ability of a series
of deletion mutants of zyxin (Fig. 5) to interact with
6E6 we demonstrated that the LIM domains are
responsible for binding this HPV protein (Fig. 6). In particular,
LIM-3, the most C-terminal LIM domain, is required for
6E6 binding, as demonstrated by the ability of LIM-2+3 but not LIM-1+2 to bind 6E6 (Fig.
6). The other two LIM domains enhance binding to
6E6, as LIM-1+2+3 binds 6E6
better than LIM-2+3 and LIM-2+3 binds better than LIM-3 (Fig. 6).
What is the function of zyxin? As noted by others the functional
conservation of the FPPPP motifs in zyxin and the ActA protein of
Listeria monocytogenes and the ability of zyxin to bind to
-actinin support a role for this protein in the organization of
actin (19, 32). However, certain features of zyxin also suggest that it may function as a signaling protein by communicating between the adhesion plaque and the nucleus. It is much less abundant than the structural components of the adhesion plaques and it has
multiple protein-binding motifs that could mediate interactions with
other proteins, including SH3 domain-bearing proteins that are
important signal transducers (for a review, see reference 8). It also has a nuclear export sequence and chicken
zyxin can shuttle between the nucleus and focal adhesions
(52). These properties are compatible with a role for
zyxin as a messenger to relay information from the extracellular matrix
to the nucleus or even to directly participate in the regulation of
gene expression. In support of the latter proposal we note that many
LIM domain proteins are well-characterized transcription factors
(3, 21). Fusion of zyxin to the Gal4-BD resulted in
transactivation in yeast (Fig. 7). Zyxin also exhibited transactivation
activity in mammalian cells (Table 1). The preliminary deletion
analysis conducted in yeast supports a role for the proline-rich region that is 5' of the LIM domains in transactivation.
While the experiments reported here make use of overexpression vectors
to demonstrate in vivo interactions, coexpression of 6E6 with the Gal4-BD fusion of FL in mammalian
cells resulted in enhanced reporter activity (Table 1). While
6E6 alone enhanced luciferase expression we
consistently observed greater stimulation when
6E6 was coexpressed with FL than when it was
expressed with Zy-5'. This might be explained by our observation that
while both of these proteins localize to the cytoplasm in the absence
of 6E6 (Fig. 8A and C) only FL is found in the
nucleus of cells cotransfected with 6E6 (Fig. 8B
versus D). The Zy-5' protein probably remained predominantly
cytoplasmic, even in the presence of 6E6 (Fig. 8C and D), because it lacks the LIM domains that are involved in interacting with 6E6 (Fig. 6). E6 proteins have
been reported to localize in the membranous compartments of the nucleus
and cytoplasm (1, 33). We found that
6E6 predominantly localized in the nucleus (Fig.
8F and H; Fig. 9D, G, J, and M). Nuclear staining of either endogenous
zyxin or the product of a cotransfected zyxin allele was only observed
in cells transfected with 6E6. Thus,
6E6 might also act as a charon and ferry
excess zyxin to the nucleus where it can be available to stimulate transcription.
lpp is a gene that is involved in lipomas
(56). It encodes a zyxin family member that shares 41%
sequence identity with zyxin, contains a proline-rich domain and three
LIM domains, and also localizes to focal adhesion plaques and points of
cell-to-cell contact. LPP was recently shown to shuttle between the
nucleus and cytoplasm and to function as a transactivator
(55). We speculate that one of the physiological functions
of zyxin family members is to shuttle to the nucleus from the cellular
membrane in response to certain extracellular stimuli. Once there, they
have the potential to activate transcription of specific genes.
6E6 may potentiate this by transporting and
retaining these proteins in the nucleus (Fig. 8 and 9).
Cell-to-cell communication and cell adhesion to an extracellular matrix
can affect cell proliferation and differentiation (17,
34). An imbalance in these activities can lead to cellular transformation. In tumor cells, disruption of adhesion plaques is a
hallmark of the transformed phenotype (14). Two other
zyxin family members have been linked to tumors. The gene encoding LPP was first identified during an analysis of chromosomal translocation events that are associated with lipomas, a group of common benign mesenchymal tumors in humans (67). The TRIP6
gene was assigned to a segment of chromosome 7q22 that is commonly
deleted in malignant myeloid diseases and uterine leiomyoma
(79). Zyxin itself has been found to interact with
differentiation proteins and proto-oncogenes (for review, see
reference8). These findings raise the possibility that
zyxin might also be linked directly or indirectly to transformation. High-risk but not low-risk E6 proteins interact with paxillin (70-72), another focal adhesion protein
(64). Here, we have described the interaction of
zyxin with 6E6, the E6 protein from the most common HPV type associated with genital warts.
 |
ACKNOWLEDGMENT |
We are grateful for the generous contributions of plasmids and
advice from M. Beckerle.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, College of Physicians and Surgeons, Columbia University, 701 W. 168th St., New York, NY 10032. Phone: (212) 305-8149. Fax: (212)
305-5106. E-mail: sjs6{at}columbia.edu.
 |
REFERENCES |
| 1.
|
Androphy, E. J.,
N. L. Hubbert,
J. T. Schiller, and D. R. Lowy.
1987.
Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines.
EMBO J.
6:989-992[Medline].
|
| 2.
|
Arber, S.,
J. J. Hunter,
J. Ross, Jr.,
M. Hongo,
G. Sansig,
J. Borg,
J. C. Perriard,
K. R. Chien, and P. Caroni.
1997.
MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure.
Cell
88:393-403[CrossRef][Medline].
|
| 3.
|
Bach, I.
2000.
The LIM domain: regulation by association.
Mech. Dev.
91:5-17[CrossRef][Medline].
|
| 4.
|
Bacharach, E., and S. P. Goff.
1998.
Binding of the human immunodeficiency virus type 1 Gag protein to the viral RNA encapsidation signal in the yeast three-hybrid system.
J. Virol.
72:6944-6949[Abstract/Free Full Text].
|
| 5.
|
Barbosa, M. S.,
D. R. Lowy, and J. T. Schiller.
1989.
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins.
J. Virol.
63:1404-1407[Abstract/Free Full Text].
|
| 6.
|
Barbosa, M. S.,
W. C. Vass,
D. R. Lowy, and J. T. Schiller.
1991.
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential.
J. Virol.
65:292-298[Abstract/Free Full Text].
|
| 7.
|
Beckerle, M. C.
1986.
Identification of a new protein localized at sites of cell-substrate adhesion.
J. Cell Biol.
103:1679-1687[Abstract/Free Full Text].
|
| 8.
|
Beckerle, M. C.
1997.
Zyxin: zinc fingers at sites of cell adhesion.
Bioessays
19:949-957[CrossRef][Medline].
|
| 9.
|
Beckmann, A. M.,
J. R. Daling,
K. J. Sherman,
C. Maden,
B. A. Miller,
R. J. Coates,
N. B. Kiviat,
D. Myerson,
N. S. Weiss,
T. G. Hislop, et al.
1989.
Human papillomavirus infection and anal cancer.
Int. J. Cancer
43:1042-1049[Medline].
|
| 10.
|
Bedell, M. A.,
K. H. Jones, and L. A. Laimins.
1987.
The E6-E7 region of human papillomavirus type 18 is sufficient for transformation of NIH 3T3 and Rat-1 cells.
J. Virol.
61:3635-3640[Abstract/Free Full Text].
|
| 11.
|
Boyer, J. L., and G. Ketner.
2000.
Genetic analysis of a potential zinc finger binding domain of the adenovirus E4 34k protein.
J. Biol. Chem.
275:14969-14978[Abstract/Free Full Text].
|
| 12.
|
Bradford, M. M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[CrossRef][Medline].
|
| 13.
|
Brown, M. C.,
J. A. Perrotta, and C. E. Turner.
1996.
Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding.
J. Cell Biol.
135:1109-1123[Abstract/Free Full Text].
|
| 14.
|
Burridge, K.
1986.
Substrate adhesions in normal and transformed fibroblasts: organization and regulation of cytoskeletal, membrane, and extracellular matrix components at focal contacts.
Cancer Rev.
4:18-78.
|
| 15.
|
Burridge, K., and M. Chrzanowska-Wodnicka.
1996.
Focal adhesion contractility and signaling, p. 137-192.
In
J. Spudich (ed.), The cytoskeleton. Annual Rev. Inc., Palo Alto, Calif.
|
| 16.
|
Chen, J. J.,
C. E. Reid,
V. Band, and E. J. Androphy.
1995.
Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein.
Science
269:529-531[Abstract/Free Full Text].
|
| 17.
|
Clark, E. A., and J. S. Brugge.
1995.
Integrins and signal transduction pathways: the road taken.
Science
268:233-239[Abstract/Free Full Text].
|
| 18.
|
Crawford, A. W., and M. C. Beckerle.
1991.
Purification and characterization of zyxin, an 82,000-dalton component of adherens junctions.
J. Biol. Chem.
266:5847-5853[Abstract/Free Full Text].
|
| 19.
|
Crawford, A. W.,
J. W. Michelsen, and M. C. Beckerle.
1992.
An interaction between zyxin and alpha-actinin.
J. Cell Biol.
116:1381-1393[Abstract/Free Full Text].
|
| 20.
|
Crawford, A. W.,
J. D. Pino, and M. C. Beckerle.
1994.
Biochemical and molecular characterization of the chicken cysteine-rich protein, a developmentally regulated LIM-domain protein that is associated with the actin cytoskeleton.
J. Cell Biol.
124:117-127[Abstract/Free Full Text].
|
| 21.
|
Dawid, I. B.,
R. Toyama, and M. Taira.
1995.
LIM domain proteins.
C. R. Acad. Sci. Ser. III
318:295-306[Medline].
|
| 22.
|
Degenhardt, Y. Y., and S. J. Silverstein.
2001.
Gps2, a protein partner for human papillomavirus E6 proteins.
J. Virol.
75:151-160[Abstract/Free Full Text].
|
| 23.
|
Drees, B.,
E. Friederich,
J. Fradelizi,
D. Louvard,
M. C. Beckerle, and R. M. Golsteyn.
2000.
Characterization of the interaction between zyxin and members of the Ena/vasodilator-stimulated phosphoprotein family of proteins.
J. Biol. Chem.
275:22503-22511[Abstract/Free Full Text].
|
| 24.
|
Drees, B. E.,
K. M. Andrews, and M. C. Beckerle.
1999.
Molecular dissection of zyxin function reveals its involvement in cell motility.
J. Cell Biol.
147:1549-1560[Abstract/Free Full Text].
|
| 25.
|
Freyd, G.,
S. K. Kim, and H. R. Horvitz.
1990.
Novel cysteine-rich motif and homeodomain in the product of the Caenorhabditis elegans cell lineage gene lin-11.
Nature
344:876-879[CrossRef][Medline].
|
| 26.
|
Gao, Q.,
A. Kumar,
S. Srinivasan,
L. Singh,
H. Mukai,
Y. Ono,
D. E. Wazer, and V. Band.
2000.
PKN binds and phosphorylates human papillomavirus E6 oncoprotein.
J. Biol. Chem.
275:14824-14830[Abstract/Free Full Text].
|
| 27.
|
Gao, Q.,
S. Srinivasan,
S. N. Boyer,
D. E. Wazer, and V. Band.
1999.
The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation.
Mol. Cell. Biol.
19:733-744[Abstract/Free Full Text].
|
| 28.
|
Gardiol, D.,
C. Kuhne,
B. Glaunsinger,
S. S. Lee,
R. Javier, and L. Banks.
1999.
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation.
Oncogene
18:5487-5496[CrossRef][Medline].
|
| 29.
|
Gill, G. N.
1995.
The enigma of LIM domains.
Structure
3:1285-1289[Medline].
|
| 30.
|
Gissmann, L.,
E. M. deVilliers, and H. zur Hausen.
1982.
Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA.
Int. J. Cancer
29:143-146[Medline].
|
| 31.
|
Gissmann, L.,
L. Wolnik,
H. Ikenberg,
U. Koldovsky,
H. G. Schnurch, and H. zur Hausen.
1983.
Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.
Proc. Natl. Acad. Sci. USA
80:560-563[Abstract/Free Full Text].
|
| 32.
|
Golsteyn, R. M.,
M. C. Beckerle,
T. Koay, and E. Friederich.
1997.
Structural and functional similarities between the human cytoskeletal protein zyxin and the ActA protein of Listeria monocytogenes.
J. Cell Sci.
110:1893-1906[Abstract].
|
| 33.
|
Grossman, S. R.,
R. Mora, and L. A. Laimins.
1989.
Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector.
J. Virol.
63:366-374[Abstract/Free Full Text].
|
| 34.
|
Gumbiner, B. M.
1996.
Cell adhesion: the molecular basis of tissue architecture and morphogenesis.
Cell
84:345-357[CrossRef][Medline].
|
| 35.
|
Hawley-Nelson, P.,
K. H. Vousden,
N. L. Hubbert,
D. R. Lowy, and J. T. Schiller.
1989.
HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.
EMBO J.
8:3905-3910[Medline].
|
| 36.
|
Heath, J. P., and G. A. Dunn.
1978.
Cell to substratum contacts of chick fibroblasts and their relation to the microfilament system. A correlated interference-reflexion and high-voltage electron-microscope study.
J. Cell Sci.
29:197-212[Medline].
|
| 37.
|
Hirota, T.,
T. Morisaki,
Y. Nishiyama,
T. Marumoto,
K. Tada,
T. Hara,
N. Masuko,
M. Inagaki,
K. Hatakeyama, and H. Saya.
2000.
Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor.
J. Cell Biol.
149:1073-1086[Abstract/Free Full Text].
|
| 38.
|
Hobert, O.,
J. W. Schilling,
M. C. Beckerle,
A. Ullrich, and B. Jallal.
1996.
SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin.
Oncogene
12:1577-1581[Medline].
|
| 39.
|
Hudson, J. B.,
M. A. Bedell,
D. J. McCance, and L. A. Laimins.
1990.
Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18.
J. Virol.
64:519-526[Abstract/Free Full Text].
|
| 40.
|
Huibregtse, J. M.,
M. Scheffner, and P. M. Howley.
1993.
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.
Mol. Cell. Biol.
13:775-784[Abstract/Free Full Text].
|
| 41.
|
Karlin, S., and G. Ghandour.
1985.
Multiple alphabet amino acid sequence comparison of the immunoglobulin -chain constant domain.
Proc. Natl. Acad. Sci. USA
82:8597-8601[Abstract/Free Full Text].
|
| 42.
|
Kiyono, T.,
A. Hiraiwa,
M. Fujita,
Y. Hayashi,
T. Akiyama, and M. Ishibashi.
1997.
Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.
Proc. Natl. Acad. Sci. USA
94:11612-11616[Abstract/Free Full Text].
|
| 43.
|
Kubbutat, M. H., and K. H. Vousden.
1998.
New HPV E6 binding proteins: dangerous liaisons?
Trends Microbiol.
6:173-175[CrossRef][Medline].
|
| 44.
|
Kuhne, C., and L. Ba |